%0 Journal Article
%T Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP
%A Adrian V. S Hill
%A Alison M. Lawrie
%A Amy Grobbelaar
%A Bebi-Yassin Rajkumar
%A Brian Angus
%A Carly Bliss
%A Chris Ockenhouse
%A Cynthia Lee
%A Danielle Morelle
%A Danny Wright
%A David J. M. Lewis
%A Diane Gbesemete
%A Georgina Bowyer
%A Graham S. Cooke
%A Hans de Graaf
%A Huw Davies
%A Ian D. Poulton
%A Johan Vekemans
%A Jonathan Powlson
%A Karen Ivinson
%A Katie J. Ewer
%A Marc Lievens
%A Navin Venkatraman
%A Nick J. Edwards
%A Rachel Roberts
%A Rich Weltzin
%A Ripley W. Ballou
%A Robert E. Sinden
%A Ruth Payne
%A Sarah Gilbert
%A Saranya Sridhar
%A Saul N. Faust
%A Stephen C. Gerry
%A Tommy Rampling
%A Ulrike Wille-Reece
%J Archive of "NPJ Vaccines".
%D 2018
%R 10.1038/s41541-018-0084-2
%X Efficacy of concomitant administration of RTS,S/AS01B with ChAd63-MVA ME-TRAP and RTS,S/AS01B immunization alone following Plasmodium falciparum 3D7 sporozoite challenge. Kaplan每Meier survival analyses. Log-rank test for significance. a Kaplan每Meier survival analysis of time to treatment following CHMI in individual groups. Mean time to diagnosis was 11.6 (㊣0.22) days for unvaccinated controls. All vaccine recipients were undiagnosed by day 23 after CHMI, or were diagnosed after the control meanˋ㊣ˋ2ˋSD. b Kaplan每Meier survival analysis of time to treatment following CHMI in pooled vaccine groups. Vaccine recipients who had received a schedule consisting of RTS,S/AS01B alone (Groups 1 and 2) were pooled, and vaccine recipients who had received a schedule consisting of RTS,S/AS01B with viral vectors expressing ME-TRAP (Groups 3 and 4) were pooled. c Kaplan每Meier survival analysis of time to first sample with >20 parasites/mL detected by quantitative polymerase chain reaction (qPCR). Mean time to this endpoint was 8.9 (㊣0.89) days for unvaccinated controls. Seven out of eight subjects in Group 1 (87.5%), 9/9 (100%) subjects in Group 2, 9/10 (90%) subjects in Group 3, and 8/9 (88.9%) subjects in Group 4 did not reach this endpoint, or did so after the control meanˋ㊣ˋ2ˋSD. d Kaplan每Meier survival analysis of time to first sample with >500 parasites/mL detected by qPCR. Mean time to this endpoint was 11.25 (㊣0.43) days for unvaccinated controls. Six out of eight subjects in Group 1 (75%), 9/9 (100%) subjects in Group 2, 7/10 (70%) subjects in Group 3, and 8/9 (88.9%) did not reach this endpoint, or did so after the control meanˋ㊣ˋ2ˋSD. R-R-R, three standard doses (50ˋ米g) of RTS,S/AS01B delivered at 4-week intervals; R-R-r, two standard doses (50ˋ米g) of RTS,S/AS01B followed by a fractional third dose (10ˋ米g). Vaccines delivered at 4-week intervals; RA-RM-RM, three standard doses (50ˋ米g) of RTS,S/AS01B delivered at 4-week intervals with concomitant administration of Chimpanzee adenovirus 63 (ChAd63) expressing multiple-epitope thrombospondin-related adhesion protein (ME-TRAP) at week 0, and modified vaccinia Ankara (MVA) expressing ME-TRAP at weeks 4 and 8; RA-RM-rM, two standard doses (50ˋ米g) of RTS,S/AS01B followed by a fractional third dose (10ˋ米g) with concomitant administration of ChAd63 ME-TRAP at week 0, and MVA ME-TRAP at weeks 4 and
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6177476/